TAAR1
Trace amine-associated receptor 1
As of the edition of 20 October 2026, TAAR1 (trace amine-associated receptor 1, UniProt Q96RJ0) has 4 drugs tested at it and 7 companies on the list, 6 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q96RJ0
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 19
- Disease areas
- Mental health; Nervous system; Ear, nose and throat; Heart and blood vessels; Lungs and airways
- Registered trials of its drugs
- 41
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Status not established | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Ulotaront | Active | Phase 3 | none listed |
| Tyramine | Went quiet | Phase 3 | none listed |
| Ralmitaront | Stopped | Phase 2 | none listed |
| Levmetamfetamine | Status not established | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 6 |
| Engaged | 1 |
| Total on the list | 7 |
| Company | Route |
|---|---|
| Roche | Route A |
| Merck & Co. | Route A |
| Teva | Route A |
The other 4 companies at TAAR1
In the product7 companies in all; 4 are not named here, and no score is.
See the 7 companies at TAAR1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.